Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05661890 |
| Other study ID # |
LokmanHekimU-SBF-HB-BA-01 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
November 15, 2022 |
| Est. completion date |
February 15, 2023 |
Study information
| Verified date |
February 2023 |
| Source |
Lokman Hekim Üniversitesi |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The elderly population and individuals with chronic diseases are at high risk for influenza
and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza
vaccine together is effective in reducing mortality as well as hospitalization rates and
costs due to pneumonia, influenza, and congestive heart disease.
This study that will be carried out will enable to determine the population-based prevalence
of the relevant vaccines in the elderly and to determine the determinants of vaccination with
the case group to be determined based on this.
The aim of the study is two phases.
1. Determination of the prevalence of seasonal influenza and pneumococcal vaccination in
elderly people over the over the age of 65 living in Ankara.
2. Investigation of socioeconomic characteristics and vaccine indecision and some
health-related determinants of vaccination through the case group created based on the
preliminary study on the prevalence of seasonal influenza and pneumococcal vaccination
in the elderly over the age of 65 living in Ankara.
The study, which includes cross-sectional prevalence and retrospective case-control stages,
is planned to be carried out with individuals over the age of 65 living in Ankara province
between November 1 and December 31, 2022.
Description:
The elderly population and individuals with chronic diseases are at high risk for influenza
and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza
vaccine together is effective in reducing mortality as well as hospitalization rates and
costs due to pneumonia, influenza, and congestive heart disease.
In recent years, progress has been made in vaccination as a result of the increase in
health-seeking behavior due to the pandemic, the greater importance of influenza and
pneumococcal vaccine application recommendations, and the perception of the prevention of
lung infections due to COVID-19.
However, the discussions on the need to predict vaccine demand and examine health behaviors,
health education, and research on new methods of vaccination efficacy in reducing future
epidemics continue to be relevant.
This study that will be carried out will enable to determine the population-based prevalence
of the relevant vaccines in the elderly and to determine the determinants of vaccination with
the case group to be determined based on this.
Research questions-Prevalence
1. What is the prevalence of influenza vaccination in the elderly?
2. What is the prevalence of pneumonia vaccination in the elderly?
Research Questions - Case Control
1. Are socio-economic characteristics (region of residence, monthly income, education,
perceived economic status) effective in vaccinating the elderly?
2. Are health-related features (chronic illness, drug use, previous vaccination status,
priority preference in health care, frequency of hospitalization and hospitalization in
the last six months, distance from health institution, self-defense behavior) effective
in vaccinating the elderly?
3. Is the vaccination attitude effective in vaccinating the elderly?
